Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Chiron, Ribozyme deal

The companies entered into an R&D agreement for the use of ribozymes to treat and/or diagnose diseases associated with cancer, and cardiovascular,

Read the full 226 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE